Thousand Oaks, CA, United States of America

Jilin Sun

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Amgen Inc.. Active years: 2011-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jilin Sun. Retrieved from https://idiyas.com/inventor/jilin-sun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jilin Sun

Introduction

Jilin Sun is a notable inventor based in Thousand Oaks, CA (US). He has made significant contributions to the field of biomedical research, particularly in the area of epidermal growth factor receptor (EGFr) binding agents. With a total of 2 patents, his work has the potential to impact therapeutic approaches in cancer treatment.

Latest Patents

Jilin Sun's latest patents focus on methods of selecting EGFr binding agents. The first patent describes methods that relate to selecting EGFr binding agents that bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, these binding agents do not bind to a panitumumab epitope on an EGFr. This innovative approach could lead to more effective treatments for patients.

Career Highlights

Jilin Sun is currently employed at Amgen Inc., a leading biotechnology company known for its focus on innovative medicines. His work at Amgen has allowed him to explore and develop new methodologies that enhance the understanding of EGFr interactions.

Collaborations

Some of Jilin Sun's coworkers include Daniel Freeman and Kenneth H Jung. Their collaborative efforts contribute to the advancement of research and development in the field of biotechnology.

Conclusion

Jilin Sun's contributions to the field of biomedical research, particularly through his patents on EGFr binding agents, highlight his innovative spirit and dedication to improving therapeutic options. His work at Amgen Inc. continues to pave the way for advancements in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…